AmivantamabMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2025
false
false
false
France
French
summary of product characteristics
amivantamab
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
EGFR Exon 20 Insertion Mutation

---
https://www.has-sante.fr/jcms/p_3505636/fr/rybrevant-amivantamab-cancer-bronchique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
carboplatin
amivantamab
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
EGFR Exon 20 Insertion Mutation
Pemetrexed
adult
package leaflet
summary of product characteristics
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
bronchial neoplasms
amivantamab

---
https://www.has-sante.fr/jcms/p_3447827/fr/rybrevant-amivantamab-cancer-bronchique
2023
France
evaluation of the transparency committee
rybrevant
amivantamab
amivantamab
bronchial neoplasms
neoplasm, malignant
Cancer
cancer
bronchus, nos

---
https://www.has-sante.fr/jcms/p_3430182/fr/rybrevant-amivantamab-cancer-bronchique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
evaluation of the transparency committee
amivantamab
carcinoma, non-small-cell lung

---
https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
2022
false
false
false
Netherlands
French
English
amivantamab
amivantamab
amivantamab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
rybrevant
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
aged
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Exon 20 Mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Gain of Function Mutation
genes, erbb-1
Refractory Lung Non-Small Cell Carcinoma
infusions, intravenous
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3336657/fr/rybrevant-amivantamab
2022
false
false
false
France
evaluation of the transparency committee
amivantamab
amivantamab
rybrevant

---
https://www.has-sante.fr/jcms/p_3345839/fr/rybrevant-amivantamab-cbnpc-avance-avec-mutation-egfr
2022
false
false
false
France
bronchial neoplasms
bronchial neoplasms
carcinoma, non-small-cell lung
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
Activating EGFR Exon 20 Mutation
evaluation of the transparency committee
amivantamab
carcinoma, non-small-cell lung
mutation

---
https://ansm.sante.fr/tableau-atu-rtu/amivantamab-50-mg-ml-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
amivantamab
treatment outcome
amivantamab
infusions, intravenous
bronchial neoplasms
adult
carcinoma, non-small-cell lung
neoplasm metastasis
Refractory Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Antineoplastic Agents, Immunological
summary of product characteristics
package leaflet
guidelines for drug use

---